ZA200306845B - Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphav beta3 antagonists. - Google Patents

Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphav beta3 antagonists.

Info

Publication number
ZA200306845B
ZA200306845B ZA200306845A ZA200306845A ZA200306845B ZA 200306845 B ZA200306845 B ZA 200306845B ZA 200306845 A ZA200306845 A ZA 200306845A ZA 200306845 A ZA200306845 A ZA 200306845A ZA 200306845 B ZA200306845 B ZA 200306845B
Authority
ZA
South Africa
Prior art keywords
preventing
methods
autoimmune disorders
treating inflammatory
integrin alphav
Prior art date
Application number
ZA200306845A
Inventor
Christine Dingivan
Ronald Wilder
Original Assignee
Medimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Inc filed Critical Medimmune Inc
Publication of ZA200306845B publication Critical patent/ZA200306845B/en

Links

ZA200306845A 2001-03-02 2003-09-02 Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphav beta3 antagonists. ZA200306845B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US27309801P 2001-03-02 2001-03-02

Publications (1)

Publication Number Publication Date
ZA200306845B true ZA200306845B (en) 2005-03-02

Family

ID=34699728

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200306845A ZA200306845B (en) 2001-03-02 2003-09-02 Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphav beta3 antagonists.

Country Status (1)

Country Link
ZA (1) ZA200306845B (en)

Similar Documents

Publication Publication Date Title
IL157706A0 (en) METHODS OF PREVENTING OR TREATING INFLAMMATORY OR AUTOIMMUNE DISORDERS BY ADMINISTERING INTEGRIN alphav beta3 ANTAGONISTS
MX249034B (en) Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions.
IL173299A0 (en) Methods of treating or preventing autoimmune diseases with 2,4- pyrimidinediamine compounds
AU4256801A (en) Treatment of movement disorders
IL168056A0 (en) Selected cgrp antagonists, method for production and use thereof as medicament
PL376373A1 (en) Selected cgrp antagonists, method for production and use thereof as medicament
IL200768A0 (en) Hematopietic cells from human embryonic stem cells
AU9684401A (en) Hedgehog antagonists, methods and uses related thereto
PL350992A1 (en) Epitopes or mimotopes derived from the c-epsilon-3 or c-epsilon-4 domains of ige, antagonists thereof, and their therapeutic uses
IL161041A0 (en) Mch antagonists for the treatment of obesity
HK1057363A1 (en) Ccr5 antagonists useful for treating aids.
DK1163264T3 (en) New LHRH antagonists with improved solubility properties
AU2003239280A1 (en) Combination treatment for depression and anxiety by nk1 and nk3 antagonists
IL163939A0 (en) Nk1 antagonists
ATE374183T1 (en) NK1 ANTAGONISTS
EP1379236A4 (en) Treatment of tics, tremors and related disorders
PL371128A1 (en) Method of treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists
MXPA03003714A (en) Crf receptor antagonists and methods relating thereto.
EP1421061A4 (en) Oxime derivatives for the treatment of dyslipidemia and hypercholesteremia
ZA200306845B (en) Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphav beta3 antagonists.
IL145024A0 (en) Epitopes or mimotopes derived from the c-epsilon-2 domain of ige, antagonists thereof, and their therapeutic uses
PL347976A1 (en) Isonipecotamides for the treatment of integrin−mediated disorders
ZA200403530B (en) Chemokine receptor antagonists and methods of use thereof.
AP2005003272A0 (en) S-Methyl-dihydro-ziprasidone for treatment of psychiatric and ocular disorder.
EP1610757A4 (en) Profiling conformational variants, antibody compositions and methods of using the same